Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1993 1
1994 1
1995 6
1996 5
1997 9
1998 6
1999 5
2000 7
2001 4
2002 5
2003 2
2004 9
2005 2
2006 2
2007 2
2008 4
2009 3
2010 4
2011 7
2012 10
2013 9
2014 4
2015 8
2016 9
2017 16
2018 12
2019 6
2020 11
2021 14
2022 12
2023 8
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

174 results

Results by year

Filters applied: . Clear all
Page 1
Role of RUNX1 in hematological malignancies.
Sood R, Kamikubo Y, Liu P. Sood R, et al. Among authors: kamikubo y. Blood. 2017 Apr 13;129(15):2070-2082. doi: 10.1182/blood-2016-10-687830. Epub 2017 Feb 8. Blood. 2017. PMID: 28179279 Free PMC article. Review.
CD146 is a potential immunotarget for neuroblastoma.
Obu S, Umeda K, Ueno H, Sonoda M, Tasaka K, Ogata H, Kouzuki K, Nodomi S, Saida S, Kato I, Hiramatsu H, Okamoto T, Ogawa E, Okajima H, Morita K, Kamikubo Y, Kawaguchi K, Watanabe K, Iwafuchi H, Yagyu S, Iehara T, Hosoi H, Nakahata T, Adachi S, Uemoto S, Heike T, Takita J. Obu S, et al. Among authors: kamikubo y. Cancer Sci. 2021 Nov;112(11):4617-4626. doi: 10.1111/cas.15124. Epub 2021 Sep 30. Cancer Sci. 2021. PMID: 34464480 Free PMC article.
Suppression of malignant rhabdoid tumors through Chb-M'-mediated RUNX1 inhibition.
Daifu T, Mikami M, Hiramatsu H, Iwai A, Umeda K, Noura M, Kubota H, Masuda T, Furuichi K, Takasaki S, Noguchi Y, Morita K, Bando T, Hirata M, Kataoka TR, Nakahata T, Kuwahara Y, Iehara T, Hosoi H, Takita J, Sugiyama H, Adachi S, Kamikubo Y. Daifu T, et al. Among authors: kamikubo y. Pediatr Blood Cancer. 2021 Feb;68(2):e28789. doi: 10.1002/pbc.28789. Epub 2020 Nov 12. Pediatr Blood Cancer. 2021. PMID: 33180377
Peripheral endomorphins drive mechanical alloknesis under the enzymatic control of CD26/DPPIV.
Komiya E, Tominaga M, Hatano R, Kamikubo Y, Toyama S, Sakairi H, Honda K, Itoh T, Kamata Y, Tsurumachi M, Kishi R, Ohnuma K, Sakurai T, Morimoto C, Takamori K. Komiya E, et al. Among authors: kamikubo y. J Allergy Clin Immunol. 2022 Mar;149(3):1085-1096. doi: 10.1016/j.jaci.2021.08.003. Epub 2021 Aug 17. J Allergy Clin Immunol. 2022. PMID: 34411589 Free article.
RUNX1-Survivin Axis Is a Novel Therapeutic Target for Malignant Rhabdoid Tumors.
Mikami M, Masuda T, Kanatani T, Noura M, Umeda K, Hiramatsu H, Kubota H, Daifu T, Iwai A, Hattori EY, Furuichi K, Takasaki S, Tanaka S, Matsui Y, Matsuo H, Hirata M, Kataoka TR, Nakahata T, Kuwahara Y, Iehara T, Hosoi H, Imai Y, Takita J, Sugiyama H, Adachi S, Kamikubo Y. Mikami M, et al. Among authors: kamikubo y. Mol Cells. 2022 Dec 31;45(12):886-895. doi: 10.14348/molcells.2022.2031. Epub 2022 Dec 12. Mol Cells. 2022. PMID: 36572559 Free PMC article.
RUNX inhibitor suppresses graft-versus-host disease through targeting RUNX-NFATC2 axis.
Kubota H, Masuda T, Noura M, Furuichi K, Matsuo H, Hirata M, Kataoka TR, Hiramatsu H, Yasumi T, Nakahata T, Imai Y, Takita J, Adachi S, Sugiyama H, Kamikubo Y. Kubota H, et al. Among authors: kamikubo y. EJHaem. 2021 May 19;2(3):449-458. doi: 10.1002/jha2.230. eCollection 2021 Aug. EJHaem. 2021. PMID: 35844683 Free PMC article.
174 results